Stereotactic Radiosurgery for Patients With Hepatic Metastases.

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed primary cancer
• * Stage IV primary disease with up to five liver metastases that are visualized on CT scan, MRI of the abdomen, or positron-emission tomography
• * No liver metastases secondary to germ cell tumor or hematologic malignancy
• * Other sites of metastases allowed
• No malignant ascites
• The cumulative total dose of radiotherapy to ≥ 2/3 of the liver and surrounding normal tissues, including the esophagus, stomach, and small bowel, must be ≤ 15 Gy
• Percutaneous or laparoscopic biopsy of the metastasis and placement of 3-5 fiducials required if undergoing Cyberknife for treatment delivery
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 60-100%
• Life expectancy ≥ 3 months
• Albumin ≥ 3 g/dL
• Alkaline phosphatase \< 1.5 times upper limit of normal (ULN)
• AST and ALT \< 1.5 times ULN
• Total bilirubin \< 1.5 times ULN
• Prothrombin time \< 1.5 times ULN
• Hemoglobin \> 10 g/dL
• Platelet count \> 100,000/mm³
• ANC \> 1,000/mm³
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No history of diagnosed inflammatory bowel disease, such as ulcerative colitis or Crohn's disease
• No active peptic ulcer disease
• No hepato-renal syndrome
• PRIOR CONCURRENT THERAPY:
• Prior systemic therapy allowed provided complete blood cell counts have recovered
• No other concurrent antineoplastic treatment